Sunday , December 22 2024
Home / Tag Archives: 3.) Swissinfo Business and Economy (page 64)

Tag Archives: 3.) Swissinfo Business and Economy

‘Looking after citizens’ ID data is a sovereign task’

e-id-referendum.ch Lawyer and parliamentarian Sibel Arslan explains why she is against the proposed new law on digital identity (eID) and why rejecting it would be an opportunity for digitisation. The government and parliament have drafted a national law on digital identity to regulate the identification of people on the internet. The vote booklet advises that the law would provide a sound basis for simple, safe and government-approved digital identities. On March 7,...

Read More »

Switzerland experiences highest unemployment rate in a decade

An extra 6,000 people registered at the unemployment office in January. © Keystone / Christian Beutler The unemployment rate in Switzerland rose again in January, reaching 3.7% – the highest level since April 2010. The impact of the coronavirus crisis continues to be felt on the Swiss economy. At the end of January, 169,753 people were registered as unemployed with the Regional Employment Offices, which is 6,208 more than the previous month. Compared to January...

Read More »

Protecting livestock from predators costs Swiss taxpayers millions

Around 90% of federal funds go towards livestock protection measures like herd-protection dogs. Keystone / Peter Schneider The federal government spends CHF4 million (around $4.4 million) a year to minimise the damage caused by predators like wolves and lynx. Of this amount some three million Swiss francs are being invested in the protection of herds and flocks, the government revealed in its response to a question from a parliamentarian. Farmers receive around 70%...

Read More »

Can Novartis really make its medicines available to everyone?

Novartis launched a new strategy in sub-Saharan Africa in 2019. Sales people will no longer be incentivised by sales targets but rather by patients reached. Reuters / Baz Ratner Novartis has said it wants everyone in the world to be able to access its products, even multi-million-dollar gene therapies. Can its experiment work? Five years ago, Swiss pharma firm Novartis did something no one else in the industry had ever done. It set out to rigorously evaluate whether...

Read More »